Symbols / CPIX Stock $4.60 +50.82% Cumberland Pharmaceuticals Inc.
CPIX (Stock) Chart
About
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Stock Fundamentals
Scroll to Statements| Market Cap | 68.80M | Enterprise Value | 44.02M | Income | -2.84M | Sales | 44.52M | Book/sh | 1.66 | Cash/sh | 0.77 |
| Dividend Yield | — | Payout | 0.00% | Employees | 93 | IPO | — | P/E | — | Forward P/E | 32.86 |
| PEG | 1.67 | P/S | 1.55 | P/B | 2.77 | P/C | — | EV/EBITDA | 32.53 | EV/Sales | 0.99 |
| Quick Ratio | 0.77 | Current Ratio | 1.01 | Debt/Eq | 41.48 | LT Debt/Eq | — | EPS (ttm) | -0.19 | EPS next Y | 0.14 |
| EPS Growth | — | Revenue Growth | 31.10% | Earnings | 2026-05-05 | ROA | -2.29% | ROE | -12.17% | ROIC | — |
| Gross Margin | 85.02% | Oper. Margin | -10.02% | Profit Margin | -6.37% | Shs Outstand | 14.96M | Shs Float | 8.72M | Short Float | 1.26% |
| Short Ratio | 1.13 | Short Interest | — | 52W High | 6.27 | 52W Low | 1.85 | Beta | -0.33 | Avg Volume | 117.36K |
| Volume | 41.87M | Target Price | — | Recom | None | Prev Close | $3.05 | Price | $4.60 | Change | 50.82% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2019-12-03 | main | B. Riley Securities | — → Buy | $10 |
| 2019-11-18 | main | B. Riley Securities | — → Buy | $9 |
| 2018-08-17 | main | B. Riley Securities | Buy → Buy | $9 |
| 2018-04-17 | init | B. Riley Securities | — → Buy | $9 |
| 2013-04-10 | main | UBS | — → Neutral | $6 |
| 2012-11-12 | main | UBS | — → Neutral | $5 |
| 2012-11-09 | down | Wells Fargo | Outperform → Market Perform | — |
- Cumberland takes $100M cash deal, keeps three Phase II programs - Stock Titan hu, 23 Apr 2026 13
- [8-K] CUMBERLAND PHARMACEUTICALS INC Reports Material Event - Stock Titan hu, 23 Apr 2026 13
- Is Cumberland (CPIX) stock a viable buying opportunity (+4.53%) 2026-04-18 - Community Sell Signals - Cổng thông tin điện tử tỉnh Lào Cai Sat, 18 Apr 2026 19
- Is Cumberland (CPIX) Stock Trending Down | Price at $3.09, Down 0.64% - Trending Entry Points - Cổng thông tin điện tử Tỉnh Sơn La Sat, 04 Apr 2026 07
- Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% Pounding - simplywall.st Fri, 06 Feb 2026 08
- Is Cumberland (CPIX) Stock at a Peak | Price at $3.23, Up 1.99% - Expert Market Insights - UBND thành phố Hải Phòng Mon, 06 Apr 2026 07
- Will Cumberland (CPIX) Stock Outperform S&P 500 | Price at $3.06, Down 1.61% - Social Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai Fri, 10 Apr 2026 07
- All-in-one H. pylori pill Talicia gets major U.S. sales push - Stock Titan Wed, 25 Feb 2026 08
- FDA clears non-opioid Caldolor for postoperative pain in adults, kids - Stock Titan hu, 16 Apr 2026 13
- Is Cumberland (CPIX) Stock at a Peak | Price at $3.23, Up 1.99% - Viral Trade Signals - Xã Thanh Hà Mon, 06 Apr 2026 07
- Experimental Duchenne drug gets FDA fast track after 5.4% heart function gain - Stock Titan Wed, 04 Feb 2026 08
- $8M 2024 Talicia Revenue — Cumberland to Commercialize FDA‑Approved H. pylori, $4M Investment - Stock Titan Mon, 20 Oct 2025 07
- New site spotlights chemo nausea patch that helps for five days - Stock Titan ue, 17 Mar 2026 07
- Cumberland Pharmaceuticals (CPIX) director receives 1,800-share stock grant - Stock Titan Fri, 20 Mar 2026 07
- Cumberland (CPIX) VP awarded 3,000 stock options at $2.80 strike - Stock Titan Fri, 20 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
44.52
+17.57%
|
37.87
-4.26%
|
39.55
-5.85%
|
42.01
|
| Operating Revenue |
|
40.40
+10.56%
|
36.54
-2.60%
|
37.51
-7.79%
|
40.68
|
| Cost Of Revenue |
|
6.67
+1.23%
|
6.59
+8.56%
|
6.07
-33.47%
|
9.12
|
| Reconciled Cost Of Revenue |
|
5.42
+2.36%
|
5.29
-37.00%
|
8.40
-5.18%
|
8.86
|
| Gross Profit |
|
37.85
+21.01%
|
31.28
-6.58%
|
33.49
+1.80%
|
32.89
|
| Operating Expense |
|
40.65
+7.77%
|
37.71
-12.37%
|
43.04
+11.51%
|
38.60
|
| Research And Development |
|
5.57
+15.58%
|
4.82
-17.45%
|
5.83
-12.78%
|
6.69
|
| Selling General And Administration |
|
31.05
+10.28%
|
28.15
-3.28%
|
29.10
+8.43%
|
26.84
|
| Selling And Marketing Expense |
|
19.10
+12.19%
|
17.02
-7.74%
|
18.45
+10.75%
|
16.66
|
| General And Administrative Expense |
|
11.95
+7.37%
|
11.13
+4.46%
|
10.65
+4.63%
|
10.18
|
| Other Gand A |
|
11.95
+7.37%
|
11.13
+4.46%
|
10.65
+4.63%
|
10.18
|
| Total Expenses |
|
47.31
+6.80%
|
44.30
-9.79%
|
49.11
+2.92%
|
47.72
|
| Operating Income |
|
-2.79
+56.59%
|
-6.43
+32.68%
|
-9.55
-67.48%
|
-5.70
|
| Total Operating Income As Reported |
|
-2.79
+56.59%
|
-6.43
+32.68%
|
-9.55
-67.48%
|
-5.70
|
| EBITDA |
|
2.97
+1528.47%
|
0.18
-92.66%
|
2.49
+646.58%
|
0.33
|
| Normalized EBITDA |
|
2.97
+5534.16%
|
-0.05
-103.29%
|
1.66
+697.57%
|
-0.28
|
| Reconciled Depreciation |
|
5.29
-12.53%
|
6.04
+4.73%
|
5.77
+8.30%
|
5.33
|
| EBIT |
|
-2.32
+60.50%
|
-5.86
-4.34%
|
-5.62
-12.45%
|
-5.00
|
| Total Unusual Items |
|
0.00
-100.00%
|
0.24
-71.15%
|
0.82
+34.43%
|
0.61
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-100.00%
|
0.24
-71.15%
|
0.82
+34.43%
|
0.61
|
| Special Income Charges |
|
0.00
-100.00%
|
0.24
-71.15%
|
0.82
+34.43%
|
0.61
|
| Other Special Charges |
|
—
|
-0.24
+71.15%
|
-0.82
-34.43%
|
-0.61
|
| Net Income |
|
-2.84
+56.23%
|
-6.48
-3.19%
|
-6.28
-12.73%
|
-5.57
|
| Pretax Income |
|
-2.81
+56.53%
|
-6.47
-2.89%
|
-6.28
-12.61%
|
-5.58
|
| Net Non Operating Interest Income Expense |
|
-0.02
+92.90%
|
-0.27
+28.86%
|
-0.38
+21.86%
|
-0.49
|
| Interest Expense Non Operating |
|
0.50
-18.09%
|
0.61
-9.34%
|
0.67
+13.97%
|
0.59
|
| Net Interest Income |
|
-0.02
+92.90%
|
-0.27
+28.86%
|
-0.38
+21.86%
|
-0.49
|
| Interest Expense |
|
0.50
-18.09%
|
0.61
-9.34%
|
0.67
+13.97%
|
0.59
|
| Interest Income Non Operating |
|
0.48
+42.55%
|
0.33
+16.59%
|
0.29
+191.50%
|
0.10
|
| Interest Income |
|
0.48
+42.55%
|
0.33
+16.59%
|
0.29
+191.50%
|
0.10
|
| Other Income Expense |
|
—
|
0.24
-93.51%
|
3.65
+497.17%
|
0.61
|
| Other Non Operating Income Expenses |
|
—
|
—
|
2.83
|
—
|
| Tax Provision |
|
0.04
+277.58%
|
-0.02
-149.53%
|
0.05
-33.52%
|
0.07
|
| Tax Rate For Calcs |
|
0.00
+6076.47%
|
0.00
-98.38%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
-100.00%
|
0.00
-99.53%
|
0.17
+34.43%
|
0.13
|
| Net Income Including Noncontrolling Interests |
|
-2.86
+55.54%
|
-6.44
-1.78%
|
-6.33
-12.05%
|
-5.65
|
| Net Income From Continuing Operation Net Minority Interest |
|
-2.84
+56.23%
|
-6.48
-3.19%
|
-6.28
-12.73%
|
-5.57
|
| Net Income From Continuing And Discontinued Operation |
|
-2.84
+56.23%
|
-6.48
-3.19%
|
-6.28
-12.73%
|
-5.57
|
| Net Income Continuous Operations |
|
-2.86
+55.54%
|
-6.44
-1.78%
|
-6.33
-12.05%
|
-5.65
|
| Net Income Discontinuous Operations |
|
—
|
—
|
—
|
0.00
|
| Minority Interests |
|
0.03
+179.28%
|
-0.04
-170.08%
|
0.05
-35.53%
|
0.08
|
| Normalized Income |
|
-2.84
+57.77%
|
-6.72
+3.07%
|
-6.93
-14.46%
|
-6.05
|
| Net Income Common Stockholders |
|
-2.84
+56.23%
|
-6.48
-3.19%
|
-6.28
-12.73%
|
-5.57
|
| Diluted EPS |
|
-0.19
+58.70%
|
-0.46
-4.55%
|
-0.44
-15.79%
|
-0.38
|
| Basic EPS |
|
-0.19
+58.70%
|
-0.46
-4.55%
|
-0.44
-15.79%
|
-0.38
|
| Basic Average Shares |
|
14.85
+5.65%
|
14.06
-1.67%
|
14.30
-1.82%
|
14.56
|
| Diluted Average Shares |
|
14.85
+5.65%
|
14.06
-1.67%
|
14.30
-1.82%
|
14.56
|
| Diluted NI Availto Com Stockholders |
|
-2.84
+56.23%
|
-6.48
-3.19%
|
-6.28
-12.73%
|
-5.57
|
| Amortization |
|
4.03
-15.03%
|
4.75
-41.40%
|
8.10
+59.90%
|
5.07
|
| Amortization Of Intangibles Income Statement |
|
4.03
-15.03%
|
4.75
-41.40%
|
8.10
+59.90%
|
5.07
|
| Depreciation Amortization Depletion Income Statement |
|
4.03
-15.03%
|
4.75
-41.40%
|
8.10
+59.90%
|
5.07
|
| Depreciation And Amortization In Income Statement |
|
4.03
-15.03%
|
4.75
-41.40%
|
8.10
+59.90%
|
5.07
|
| Earnings From Equity Interest Net Of Tax |
|
-0.01
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
76.82
+1.64%
|
75.58
-7.57%
|
81.78
-12.00%
|
92.93
|
| Current Assets |
|
37.06
+1.67%
|
36.45
+2.07%
|
35.71
-22.14%
|
45.87
|
| Cash Cash Equivalents And Short Term Investments |
|
11.44
-36.29%
|
17.96
-1.95%
|
18.32
-7.27%
|
19.76
|
| Cash And Cash Equivalents |
|
11.44
-36.29%
|
17.96
-1.95%
|
18.32
-7.27%
|
19.76
|
| Receivables |
|
16.94
+44.81%
|
11.70
+19.91%
|
9.76
-25.87%
|
13.16
|
| Accounts Receivable |
|
16.94
+44.81%
|
11.70
+19.91%
|
9.76
-25.87%
|
13.16
|
| Gross Accounts Receivable |
|
25.94
+102.67%
|
12.80
+23.59%
|
10.36
-24.74%
|
13.76
|
| Allowance For Doubtful Accounts Receivable |
|
-9.00
-718.18%
|
-1.10
-83.33%
|
-0.60
+0.00%
|
-0.60
|
| Inventory |
|
6.23
+55.64%
|
4.00
-13.22%
|
4.61
-53.27%
|
9.86
|
| Raw Materials |
|
9.83
-17.94%
|
11.98
-5.05%
|
12.62
-2.17%
|
12.90
|
| Finished Goods |
|
5.65
+94.88%
|
2.90
-37.63%
|
4.65
+7.47%
|
4.32
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
2.45
-12.25%
|
2.79
-7.89%
|
3.03
-1.94%
|
3.08
|
| Total Non Current Assets |
|
39.76
+1.62%
|
39.13
-15.05%
|
46.06
-2.11%
|
47.05
|
| Net PPE |
|
8.61
+33.38%
|
6.45
-8.35%
|
7.04
+27.98%
|
5.50
|
| Gross PPE |
|
11.11
+25.60%
|
8.85
-4.68%
|
9.28
+22.31%
|
7.59
|
| Accumulated Depreciation |
|
-2.50
-4.62%
|
-2.39
-6.87%
|
-2.24
-7.33%
|
-2.09
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
1.93
+4.41%
|
1.84
+2.17%
|
1.81
+14.13%
|
1.58
|
| Leases |
|
9.19
+31.18%
|
7.00
-6.33%
|
7.48
+24.46%
|
6.01
|
| Goodwill And Other Intangible Assets |
|
14.94
-20.89%
|
18.89
-19.70%
|
23.52
-25.34%
|
31.50
|
| Goodwill |
|
0.91
+0.00%
|
0.91
+0.00%
|
0.91
+0.00%
|
0.91
|
| Other Intangible Assets |
|
14.03
-21.95%
|
17.97
-20.50%
|
22.61
-26.10%
|
30.59
|
| Investments And Advances |
|
3.99
|
0.00
|
—
|
—
|
| Other Non Current Assets |
|
12.23
-11.34%
|
13.79
-11.02%
|
15.50
+54.24%
|
10.05
|
| Total Liabilities Net Minority Interest |
|
52.28
-1.43%
|
53.04
+0.99%
|
52.52
-7.79%
|
56.95
|
| Current Liabilities |
|
36.74
+16.20%
|
31.62
+13.01%
|
27.98
-2.09%
|
28.58
|
| Payables And Accrued Expenses |
|
21.35
+33.56%
|
15.99
-5.10%
|
16.85
+13.56%
|
14.84
|
| Payables |
|
18.57
+33.44%
|
13.91
-0.88%
|
14.04
+29.75%
|
10.82
|
| Accounts Payable |
|
18.57
+33.44%
|
13.91
-0.88%
|
14.04
+29.75%
|
10.82
|
| Current Accrued Expenses |
|
2.79
+34.34%
|
2.07
-26.19%
|
2.81
-30.06%
|
4.02
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.48
+23.17%
|
1.20
+0.25%
|
1.20
-16.87%
|
1.44
|
| Current Debt And Capital Lease Obligation |
|
0.47
-91.43%
|
5.46
+1467.55%
|
0.35
+101.31%
|
0.17
|
| Current Debt |
|
—
|
5.10
|
—
|
—
|
| Other Current Borrowings |
|
—
|
5.10
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.47
+31.21%
|
0.36
+2.42%
|
0.35
+101.31%
|
0.17
|
| Current Deferred Liabilities |
|
0.03
-87.93%
|
0.21
-6.05%
|
0.22
-64.14%
|
0.61
|
| Other Current Liabilities |
|
13.42
+53.03%
|
8.77
-6.40%
|
9.37
-18.64%
|
11.52
|
| Total Non Current Liabilities Net Minority Interest |
|
15.53
-27.46%
|
21.42
-12.71%
|
24.53
-13.53%
|
28.37
|
| Long Term Debt And Capital Lease Obligation |
|
9.71
-35.75%
|
15.12
-16.40%
|
18.08
-13.02%
|
20.79
|
| Long Term Debt |
|
5.24
-48.50%
|
10.18
-20.40%
|
12.78
-21.09%
|
16.20
|
| Long Term Capital Lease Obligation |
|
4.47
-9.47%
|
4.94
-6.73%
|
5.30
+15.48%
|
4.59
|
| Non Current Deferred Liabilities |
|
3.38
+6.44%
|
3.17
+9.59%
|
2.89
+14.76%
|
2.52
|
| Other Non Current Liabilities |
|
0.25
+0.00%
|
0.25
-8.76%
|
0.27
+109.16%
|
0.13
|
| Stockholders Equity |
|
24.88
+8.87%
|
22.85
-22.80%
|
29.60
-18.37%
|
36.27
|
| Common Stock Equity |
|
24.88
+8.87%
|
22.85
-22.80%
|
29.60
-18.37%
|
36.27
|
| Capital Stock |
|
51.68
+10.39%
|
46.82
-0.57%
|
47.09
-0.81%
|
47.47
|
| Common Stock |
|
51.68
+10.39%
|
46.82
-0.57%
|
47.09
-0.81%
|
47.47
|
| Share Issued |
|
14.96
+7.20%
|
13.95
-1.20%
|
14.12
-1.70%
|
14.37
|
| Ordinary Shares Number |
|
14.96
+7.20%
|
13.95
-1.20%
|
14.12
-1.70%
|
14.37
|
| Retained Earnings |
|
-26.80
-11.83%
|
-23.97
-37.05%
|
-17.49
-56.02%
|
-11.21
|
| Minority Interest |
|
-0.34
-9.29%
|
-0.31
+10.49%
|
-0.34
-17.61%
|
-0.29
|
| Total Equity Gross Minority Interest |
|
24.54
+8.86%
|
22.55
-22.95%
|
29.26
-18.66%
|
35.97
|
| Total Capitalization |
|
30.12
-8.81%
|
33.03
-22.08%
|
42.39
-19.21%
|
52.47
|
| Working Capital |
|
0.32
-93.47%
|
4.83
-37.53%
|
7.73
-55.28%
|
17.29
|
| Invested Capital |
|
30.12
-21.00%
|
38.13
-10.05%
|
42.39
-19.21%
|
52.47
|
| Total Debt |
|
10.18
-50.51%
|
20.57
+11.63%
|
18.43
-12.07%
|
20.96
|
| Capital Lease Obligations |
|
4.94
-6.73%
|
5.30
-6.17%
|
5.64
+18.60%
|
4.76
|
| Net Tangible Assets |
|
9.94
+150.59%
|
3.97
-34.79%
|
6.08
+27.72%
|
4.76
|
| Tangible Book Value |
|
9.94
+150.59%
|
3.97
-34.79%
|
6.08
+27.72%
|
4.76
|
| Inventories Adjustments Allowances |
|
-9.25
+15.92%
|
-11.01
+14.05%
|
-12.80
-70.11%
|
-7.53
|
| Line Of Credit |
|
—
|
—
|
—
|
—
|
| Non Current Accrued Expenses |
|
2.20
-23.70%
|
2.88
-12.40%
|
3.28
-33.39%
|
4.93
|
| Other Inventories |
|
—
|
0.13
-15.77%
|
0.15
-11.38%
|
0.17
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
4.93
+905.72%
|
-0.61
-110.05%
|
6.09
-27.91%
|
8.45
|
| Cash Flow From Continuing Operating Activities |
|
4.93
+905.72%
|
-0.61
-110.05%
|
6.09
-27.91%
|
8.45
|
| Cash From Discontinued Operating Activities |
|
—
|
—
|
—
|
0.00
|
| Net Income From Continuing Operations |
|
-2.86
+55.54%
|
-6.44
-1.78%
|
-6.33
-12.05%
|
-5.65
|
| Depreciation Amortization Depletion |
|
5.29
-12.53%
|
6.04
+4.73%
|
5.77
+8.30%
|
5.33
|
| Depreciation |
|
1.25
-3.38%
|
1.30
-77.56%
|
5.77
+8.30%
|
5.33
|
| Amortization Cash Flow |
|
4.03
-15.03%
|
4.75
|
—
|
5.07
|
| Depreciation And Amortization |
|
5.29
-12.53%
|
6.04
+4.73%
|
5.77
+8.30%
|
5.33
|
| Amortization Of Intangibles |
|
4.03
-15.03%
|
4.75
|
—
|
5.07
|
| Other Non Cash Items |
|
-0.07
+95.96%
|
-1.81
-5.83%
|
-1.71
+19.06%
|
-2.11
|
| Stock Based Compensation |
|
0.41
+35.25%
|
0.30
-17.30%
|
0.37
-18.43%
|
0.45
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
3.34
|
0.00
|
| Deferred Tax |
|
—
|
—
|
—
|
0.00
|
| Deferred Income Tax |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
0.01
+391.27%
|
0.00
-86.72%
|
0.02
|
—
|
| Gain Loss On Investment Securities |
|
0.01
|
—
|
—
|
—
|
| Change In Working Capital |
|
2.16
+67.26%
|
1.29
-72.10%
|
4.63
-55.61%
|
10.44
|
| Change In Receivables |
|
-5.24
-169.82%
|
-1.94
-157.07%
|
3.40
+155.68%
|
-6.12
|
| Changes In Account Receivables |
|
-5.24
-169.82%
|
-1.94
-157.07%
|
3.40
+155.68%
|
-6.12
|
| Change In Inventory |
|
2.24
-6.88%
|
2.41
+10506.59%
|
-0.02
-102.54%
|
0.91
|
| Change In Payables And Accrued Expense |
|
6.71
+776.77%
|
-0.99
-126.62%
|
3.72
-74.38%
|
14.54
|
| Change In Payable |
|
6.71
+776.77%
|
-0.99
-126.62%
|
3.72
-74.38%
|
14.54
|
| Change In Account Payable |
|
6.71
+776.77%
|
-0.99
-126.62%
|
3.72
-74.38%
|
14.54
|
| Change In Other Current Assets |
|
-0.23
-222.59%
|
0.19
+187.91%
|
0.07
-90.47%
|
0.69
|
| Change In Other Current Liabilities |
|
-1.31
-180.58%
|
1.63
+164.27%
|
-2.54
-704.49%
|
0.42
|
| Investing Cash Flow |
|
-4.71
-8236.82%
|
0.06
+154.73%
|
-0.11
+99.23%
|
-13.67
|
| Cash Flow From Continuing Investing Activities |
|
-4.71
-8236.82%
|
0.06
+154.73%
|
-0.11
+99.23%
|
-13.67
|
| Net PPE Purchase And Sale |
|
-0.10
-47.31%
|
-0.07
+76.37%
|
-0.28
-175.35%
|
-0.10
|
| Purchase Of PPE |
|
-0.10
-47.31%
|
-0.07
+76.37%
|
-0.28
-175.35%
|
-0.10
|
| Capital Expenditure |
|
-0.18
-1.44%
|
-0.18
+60.33%
|
-0.45
+78.15%
|
-2.07
|
| Net Investment Purchase And Sale |
|
-4.48
|
0.00
|
—
|
0.00
|
| Purchase Of Investment |
|
-4.48
|
0.00
|
—
|
0.00
|
| Sale Of Investment |
|
—
|
—
|
—
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-13.50
|
| Purchase Of Business |
|
—
|
—
|
0.00
+100.00%
|
-13.50
|
| Net Intangibles Purchase And Sale |
|
-0.08
+25.47%
|
-0.11
+34.07%
|
-0.17
+91.29%
|
-1.97
|
| Purchase Of Intangibles |
|
-0.08
+25.47%
|
-0.11
+34.07%
|
-0.17
+91.29%
|
-1.97
|
| Net Other Investing Changes |
|
-0.05
-119.78%
|
0.24
-31.61%
|
0.35
-81.71%
|
1.90
|
| Financing Cash Flow |
|
-6.75
-3525.79%
|
0.20
+102.65%
|
-7.42
-260.10%
|
-2.06
|
| Cash Flow From Continuing Financing Activities |
|
-6.75
-3525.79%
|
0.20
+102.65%
|
-7.42
-260.10%
|
-2.06
|
| Net Issuance Payments Of Debt |
|
-10.04
-502.70%
|
2.49
+172.95%
|
-3.42
-384.65%
|
1.20
|
| Issuance Of Debt |
|
0.00
-100.00%
|
38.49
+22.28%
|
31.48
-40.50%
|
52.90
|
| Repayment Of Debt |
|
-10.04
+72.12%
|
-36.00
-3.17%
|
-34.89
+32.51%
|
-51.70
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
38.49
+22.28%
|
31.48
-40.50%
|
52.90
|
| Long Term Debt Payments |
|
-10.04
+72.12%
|
-36.00
-3.17%
|
-34.89
+32.51%
|
-51.70
|
| Net Long Term Debt Issuance |
|
-10.04
-502.70%
|
2.49
+172.95%
|
-3.42
-384.65%
|
1.20
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
5.00
+963.98%
|
-0.58
+21.81%
|
-0.74
+29.68%
|
-1.05
|
| Common Stock Payments |
|
-0.26
+54.50%
|
-0.58
+21.81%
|
-0.74
+29.68%
|
-1.05
|
| Repurchase Of Capital Stock |
|
-0.26
+54.50%
|
-0.58
+21.81%
|
-0.74
+29.68%
|
-1.05
|
| Net Other Financing Charges |
|
-1.71
+0.18%
|
-1.72
+47.49%
|
-3.27
-47.96%
|
-2.21
|
| Changes In Cash |
|
-6.52
-1723.94%
|
-0.36
+75.11%
|
-1.44
+80.28%
|
-7.28
|
| Beginning Cash Position |
|
17.96
-1.95%
|
18.32
-7.27%
|
19.76
-26.93%
|
27.04
|
| End Cash Position |
|
11.44
-36.29%
|
17.96
-1.95%
|
18.32
-7.27%
|
19.76
|
| Free Cash Flow |
|
4.75
+699.85%
|
-0.79
-114.04%
|
5.64
-11.58%
|
6.38
|
| Interest Paid Supplemental Data |
|
0.44
-22.41%
|
0.57
-12.04%
|
0.65
+23.70%
|
0.52
|
| Income Tax Paid Supplemental Data |
|
—
|
0.01
-86.22%
|
0.11
+3197.67%
|
0.00
|
| Common Stock Issuance |
|
5.27
|
0.00
|
—
|
—
|
| Issuance Of Capital Stock |
|
5.27
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-23 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-18 View
- 10-K2026-03-09 View
- 8-K2026-03-03 View
- 8-K2026-02-04 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42025-12-01 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|